Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2005 1
2006 3
2008 3
2009 3
2010 3
2011 1
2012 2
2013 2
2014 6
2015 6
2016 9
2017 4
2018 3
2019 2
2020 4
2021 10
2022 7
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study.
Minson A, Hamad N, Cheah CY, Tam C, Blombery P, Westerman D, Ritchie D, Morgan H, Holzwart N, Lade S, Anderson MA, Khot A, Seymour JF, Robertson M, Caldwell I, Ryland G, Saghebi J, Sabahi Z, Xie J, Koldej R, Dickinson M. Minson A, et al. Among authors: lade s. Blood. 2024 Feb 22;143(8):673-684. doi: 10.1182/blood.2023021306. Blood. 2024. PMID: 37883795 Clinical Trial.
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I; Australian Ovarian Cancer Study Group; Gertig D, DeFazio A, Bowtell DD. Tothill RW, et al. Among authors: lade s. Clin Cancer Res. 2008 Aug 15;14(16):5198-208. doi: 10.1158/1078-0432.CCR-08-0196. Clin Cancer Res. 2008. PMID: 18698038
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, Burbury K, Turner G, Di Iulio J, Bressel M, Westerman D, Lade S, Dreyling M, Dawson SJ, Dawson MA, Seymour JF, Roberts AW. Tam CS, et al. Among authors: lade s. N Engl J Med. 2018 Mar 29;378(13):1211-1223. doi: 10.1056/NEJMoa1715519. N Engl J Med. 2018. PMID: 29590547 Free article. Clinical Trial.
Mycosis fungoides and Sézary syndrome: Australian clinical practice statement.
Bhabha FK, McCormack C, Wells J, Campbell BA, Newland K, Lade S, Buelens O, Joske D, Shortt J, Mapp S, Radeski D, Hertzberg M, Khot A, Van Der Weyden C, Khoo C, Hawkes E, Prince HM. Bhabha FK, et al. Among authors: lade s. Australas J Dermatol. 2021 Feb;62(1):e8-e18. doi: 10.1111/ajd.13467. Epub 2020 Dec 26. Australas J Dermatol. 2021. PMID: 33368169 Review.
Defining double-hit lymphoma in the clinic.
Blombery P, Lade S. Blombery P, et al. Among authors: lade s. Blood. 2021 Apr 22;137(16):2132-2133. doi: 10.1182/blood.2020009465. Blood. 2021. PMID: 33885709 Free article. No abstract available.
The efficacy of methotrexate for lymphomatoid papulosis.
Newland KM, McCormack CJ, Twigger R, Buelens O, Hughes CF, Lade S, Dickinson M, Yap LM, Ryan G, Prince HM. Newland KM, et al. Among authors: lade s. J Am Acad Dermatol. 2015 Jun;72(6):1088-90. doi: 10.1016/j.jaad.2015.03.001. J Am Acad Dermatol. 2015. PMID: 25981010 No abstract available.
61 results